psychosocial well-being (2) . For this purpose, gonadotropinreleasing hormone agonists (GnRHa) have been widely used for the treatment of CPP for more than 30 years. GnRHa treatment that effectively inhibits gonadotropin secretion is generally a reliable treatment in children (2) . In longterm follow-up studies, it was shown to increase final adult height in children with CPP but it did not show significant changes in reproductive activity (3) . Studies on the efficacy and the auxological effects of GnRHa treatment in CPP are mainly related to revealing adult height gain (4) . The results in the studies conducted about the effect of GnRHa treatment on body weight are contradictory. While it is reported in some studies that GnRHa treatment is linked with body fat mass, body weight and body mass index (BMI) increases (4) (5) (6) (7) (8) (9) (10) , it is reported not to be linked in other studies (3, 5, 9, 11, 12) . Even some studies reported that it was associated with a decrease in BMI (12, 13) .
Nutrition and body fat mass during childhood are closely related to PP. Considering the increasing prevalence of obesity all over the world and the higher prevalence of PP in obese people compared to the normal population (14) (15) (16) (17) , the importance of the effects of GnRHa treatment used for PP on body weight is increasing day by day.
The aim of this study was to evaluate the effects of the GnRHa treatment on BMI and height in female patients with central PP.
Materials and Methods
In this study, the records of patients who were diagnosed with PP in the Konya Training and Research Hospital, Clinic of Paediatric Endocrinology Outpatient between 2010 and 2018 were retrospectively reviewed. The study was approved by the Necmettin Erbakan University Faculty of Medicine Local Ethics Committee (approval number: 2017/1100). Informed consent was obtained. A total of 114 female patients, who received GnRHa treatment and were in the age group of 1.65-8.9 years, including 22 patients (19.3%) followed up with the diagnosis of PP (organic CPP) associated with an organic disorder of central neural system and 92 patients (80.7%) followed up with the diagnosis of idiopathic CPP were included in the study.
Idiopathic CPP criteria were taken as follows: 1) the onset of budding in the breasts before the age of 8 years in girls, 2) determination of at least 1 year advanced bone age compared to chronological age, 3) the peak luteinizing hormone (LH) ≥5 mIU/mL examined with chemiluminescence immunoassay method after the exogenous GnRH (gonadorelin 100 µg) intravenous injection, 4) a lack of a history suggesting a central nervous system disease and the presence of normal cranial magnetic resonance imaging (MRI) symptoms (18) . Patients with a history of central nervous system disease and/or pathological cranial MRI symptoms were accepted as central PP (organic CPP) developing secondarily to central nervous system pathologies. Patients who used drugs that might affect anthropometric measures and had a systemic disease such as hypothyroidism, congenital adrenal hyperplasia or Cushing's disease were excluded from the study.
From the outpatient clinic file records of patients, their weight, height, puberty phase according to Marshall and Tanner (19) , basal serum LH, follicle stimulating hormone (FSH), and estradiol studied from venous blood samples taken between 08.00-12.00 after 12-hour fasting, peak serum LH level after exogenous GnRH (gonadorelin 100 µg) intravenous injection, bone age assessment according to the Greulich and Pyle (20) method, and cranial imaging results were recorded. BMI of the patients was calculated with weight (kg) -height (cm) 2 by using their weight and height measurements; height standard deviation score (SDS), BMI SDS, BMI percentile values were obtained using standardized data prepared for Turkish children based on age and gender (21) . BMI ≥95 percentile was considered as obese, 85-95 percentile as overweight, and <85 percentile as normal body weight. Predicted adult height (PAH) according to bone age was calculated according to the Bayley and Pinneau (22) method. Height SDS, BMI SDS, BMI percentile, and PAH value were calculated from the height, weight and bone age data for the 6 th month, 1 st year and 2 nd year of the treatment in the follow-up of patients.
In the routine protocol of the clinic of paediatric endocrinology outpatient; for the treatment of PP, GnRHa leuprolide (Lucrin 3.75 mg depot) or triptorelin (Decapeptyl 3.75 mg depot) is intramuscularly administered every 28 days with a dose of 3.75 mg if the patient has a weight >20 kg and with a dose of 1.875 mg if the patient has a weight <20 kg (2) . Patients undergoing treatment are followed up with anthropometric measurements, pubertal symptoms, and serum LH levels every 3 months. During the follow-up, serum LH level <3 mIU/mL at 60 th minute after GnRHa injection is accepted as suppressed HPG axis; serum LH level ≥3 mIU/mL is accepted as non-suppressed axis (23) and the axis is checked again in terms of suppression with a standard GnRH test in the 3 rd week of GnRHa injection. A peak LH level <2 mIU/mL in the standard GnRH test is considered as suppressed HPG axis, while a peak LH ≥2 mIU/mL is considered as non-suppressed axis (24) and GnRHa treatment dose is increased to 7.5 mg/28 days. The data of the patients, who were followed up in this context and were diagnosed with central PP, and received GnRHa treatment, were included in the study. Serum LH, FSH, and estradiol levels were studied in the Biochemistry Laboratory of Konya Training and Research Hospital using an ADVİA Centaur XP (Siemens Healthcare Diagnostics, Camberley, UK) device with a chemiluminescence immunoassay method.
Statistical Analysis
For statistical analyses, the IBM SPSS Statistics version 22 (IBM Corporation, Armonk, NY, United States of America) program was used. The data were determined as mean ± standard deviation and the significance limit for all statistics was accepted as p<0.05. In order to decide the appropriate test statistics in the evaluation of data, first the suitability of data to normal distribution was tested by applying Kolmogorov-Smirnov test statistics. In the numeric data, Student's t-test in two-group comparisons for the data meeting normal distribution; Mann-Whitney U test for comparison of data that did not show normal distribution; ANOVA in the comparison of repeated measurements in the same group; chi-square and Fisher's exact tests in the comparison of qualitative data were used.
Results
The admission average age was 7.84±1.01 years in the idiopathic CPP group and 7.57±1.03 years in the organic CPP group. The bone age at the beginning of the treatment was 9.99±1.13 years in the idiopathic CPP group and 9.44±1.5 years in the organic CPP group. Admission age, age at beginning of treatment, bone age, bone age-age at beginning of treatment difference, basal LH, FSH, estradiol and peak LH responses to classical GnRH test were similar in the idiopathic and organic CPP groups (Table I) .
The mean BMI SDS increased during treatment in all patients receiving GnRHa treatment. BMI SDS statistically significantly increased in the 1 st year (0.67±0.12 and 0.88±0.12, p<0.001) and 2 nd year (0.67±0.12 and 0.89±0.11, p=0.005) compared to the beginning of treatment, in the 1 st year (0.73±0.12 and 0.88±0.12, p=0.014) and 2 nd year (0.73±0.12 and 0.89±0.11, p=0.023) compared to the 6 th month of treatment (Table II) .
When examining the mean BMI SDS values of the patients in the groups, it was determined that there was a significant increase in BMI SDS in the 1 st year compared to the beginning of treatment in patients with idiopathic CPP (0.63±0.88 and 0.76±0.84, p=0.006). A significant increase was found in BMI SDS in the 2 nd year compared to the beginning of treatment in the organic CPP group (0.80±0.97 and 1.35±0.72, p=0.029). Although BMI SDS was not different between the two groups in the 6 th month and 1 st year of GnRHa treatment, BMI SDS was significantly higher in the organic CPP group compared to the idiopathic CPP group in the 2 nd year of the treatment (0.66±0.84 and 1.35±0.72, p=0.007) (Table III) .
In the patients who had normal weight at the beginning of GnRHa treatment in both groups, the BMI SDS increase No significant change was observed in the BMI SDS during treatment of those patients who were overweight-obese at the beginning of GnRHa treatment in both groups (Table  IV) .
While 34% of the patients in the idiopathic CPP group were overweight-obese (21%, 13%) at the beginning of the treatment, this rate was determined as 45% (25%, 20%) in the organic CPP group. An increase was observed in the frequency of overweight-obese patients undergoing GnRHa treatment in the organic CPP group (50%, 59%, and 64%, respectively in the 6 th month, 1 st year, and 2 nd year of treatment). The frequency of obese patients with BMI >95 percentile was higher in the organic CPP group compared to the idiopathic CPP group both in the 1 st year (47% and 18%, p=0.039) and 2 nd year (57% and 19%, p=0.02) of GnRHa treatment (Figure 1 ).
In patients with idiopathic CPP, the 2 nd year height SDS was significantly lower compared to the beginning of treatment (1.05±1.03 and 0.74±1.06, p=0.024); whereas, height SDS according to bone age was significantly higher in the 2 nd year compared to the beginning of treatment (-1.01±0.95 and -0.68±0.72, p=0.03). Similarly, the height SDS of patients with organic CPP was significantly higher based on bone age compared to the beginning of treatment (- Table V) .
The average treatment durations were 2.8±0.84 and 2.62±0.51 years, respectively for the patients with idiopathic CPP and organic CPP (p>0.05). In both groups, 65% of the patients were using leuprolide and 35% were using triptorelin and there was no difference between the groups in terms of the frequency of medication usage. Cranial imaging was performed in 104 patients from 114 patients included in the study and pathological findings were determined in 22 of them (organic CPP). Pathologies detected in cranial imaging were: septum pellucidum anomaly (n=1), hypothalamic 
Discussion
This study investigated the effect of GnRHa treatment on body weight and height in female patients suffering from central PP for both idiopathic and organic reasons.
The present study revealed that GnRHa treatment in patients with CPP caused an increase in BMI SDS, that patients with organic CPP were more prone to the increase in weight and BMI, and the patients had height gain after undergoing the GnRHa treatment.
In the literature, the results of studies evaluating the effects of GnRHa treatment on body weight and BMI are controversial and incompatible with each other. There are studies reporting that GnRHa treatment is linked with body weight, BMI and BMI SDS increases in patients with CPP (4, 6, 9, 10, (25) (26) (27) (28) (29) , whereas with other studies, GnRHa treatment is not linked with them (3, 5, 9, 11, 12, (30) (31) (32) (33) , and even GnRHa treatment decreases BMI (12, 13) . The reason for the inconsistency between studies is not clear.
Possible causes may include different designs of studies, heterogeneous etiology including idiopathic and organic etiology, different gender and age ranges, different body weights at the beginning of GnRHa treatment, different treatment strategies, and different follow-up intervals. In a recent study conducted in Spain to evaluate BMI SDS of 333 patients with CPP who received GnRHa treatment, a significant increase was determined in BMI SDS during treatment and this increase was reported to continue after the interruption of the GnRHa treatment and reaching adult height (10) . Similarly, in the present study, the average BMI SDS of all our patients who received GnRHa treatment increased both in the 1 st and 2 nd years compared to the beginning of treatment and in the 1 st and 2 nd years compared to the 6 th month (Table II) . These results suggest that GnRHa treatment is associated with an increase in BMI and weight gain. The mechanism of GnRHa treatment causing an increase in body weight and BMI is not exactly known. There is a need for further studies on this subject that will explain the mechanism and evaluate adipokine levels involved in the energy-gonad axis such as leptin, neuropeptide Y, insulin and ghrelin.
In the present study, 1 st year BMI SDS in the idiopathic CPP group and 2 nd year BMI SDS in the organic CPP group showed a significant increase compared to the beginning of treatment. In the organic CPP group, the 2 nd year average BMI SDS values were higher than the idiopathic CPP group (0.66±0.84 and 1.35±0.72, p=0.007) (Table III) . These results revealed that GnRHa treatment caused an increase in weight and BMI in patients with both idiopathic CPP and organic CPP and the weight gain and prevalence of overweight-obesity were higher in the organic CPP group compared to the idiopathic CPP group. In the literature, there are a limited number of studies comparing the effects of GnRHa treatment on body weight and BMI in idiopathic and organic CPP groups. Feuillan et al. (26) reported in their study conducted with 18 patients with CPP caused by hypothalamic hamartoma HH-CPP and 32 patients with idiopathic CPP who received GnRHa treatment that BMI SDS was higher in patients with HH-CPP compared to the idiopathic CPP group at the beginning of the treatment, termination of the treatment and during the follow-up period after the treatment. In another study conducted to evaluate the patients with HH-CPP who received GnRHa treatment, the prevalence of overweight and obesity was reported to be high in female patients with HH-CPP (34) . The structural central disorder causing organic pathology in patients with organic CPP is likely to cause more weight gain by causing changes in the neuronal network of the central nervous system associated with obesity and in neurotransmitters. There is a need for more related studies which include more organic CPP and control groups. In addition to the studies reporting that the increase in BMI SDS and obesity prevalence for patients receiving GnRHa treatment is observed in those children who were overweight before the treatment (5, 35) , there are also other studies reporting that the patients who had normal weight at the beginning of treatment had more weight gain with GnRHa treatment compared to the overweightobese patients (11, 36, 37) . In the present study, a significant increase was observed in BMI SDS in both the 1 st year and 2 nd year of the treatment in patients who had normal weight at the beginning of treatment in both groups (Table IV) . No significant change was observed in BMI SDS during the treatment period in those patients who were overweightobese at the beginning of treatment in both groups. The present study showed that patients who had a normal weight at the beginning of treatment had the tendency to have more weight gain during the treatment and the weight at the beginning of the treatment affected the weight gain associated with GnRHa treatment. The fact that the patients who were overweight and obese at the beginning of the treatment, and their parents, were more susceptible to the possible weight gain that could develop with the treatment and so had the tendency to take measures such as diet, physical activity, and sleep regulation to prevent obesity is believed to contribute to the lower weight gain in this group. According to the Cosi-Tur 2016 study conducted by the Ministry of Health (38) , it was found that the prevalence of overweight and obesity was 24.2% in girls who were aged between 6-9 years in Turkey, the prevalence of overweight and obesity was higher with the rate of 34% in the idiopathic CPP group and 45% in the organic CPP group compared to the reference age group in our patients who were in a similar age group at the beginning of their treatment (Figure 1 ). Similar to the results of the present study, Anık et al. (35) reported that the overweight prevalence and obesity prevalence in patients with PP before GnRHa treatment were higher than the average of the population with rates of 37.5% and 21.9%, respectively. The high obesity prevalence determined at the beginning of GnRHa treatment in the present study shows a correlation between the obesity and PP.
In the literature, the results reporting on the prevalence of overweight-obesity in the follow-ups of GnRHa treatment in patients with CPP are contradictory similar to BMI and BMI SDS results (11, 12, 35) . In the present study, the rate of overweight-obese patients in the idiopathic CPP group which was 34% before the treatment, increased by 42.2% in the 1 st year and by 38% in the 2 nd year but it was not found to be statistically significant. In the organic CPP group, the prevalence of overweight-obese patients showed a significant increase at the beginning, the 1 st year, and the 2 nd year of the treatment with 45%, 59% and 64%, respectively. The rate of overweight-obese patients was found to be higher in the 1 st and 2 nd year of the treatment in the organic CPP group compared to the idiopathic CPP group (Figure 1 ). Especially cases with organic CPP receiving GnRHa treatment should be monitored more carefully in terms of weight gain and risk factors that may contribute to weight gain should be eliminated during the follow-up.
In the present study, while height SDS did not change in the idiopathic and organic CPP groups in the 1 st year of GnRHa treatment, it decreased in the 2 nd year of treatment in the idiopathic group compared to the basal. In both groups, an increase was observed in height SDS according to bone age (Table V) . Similarly, Weise et al. (39) reported that height SDS decreased according to age and height SDS increased according to bone age in 100 female patients with CPP receiving GnRHa treatment. Slowness in the rapid height increase, decrease in height SDS according to age and increase in height SDS according to bone age as a result of the rapid bone maturation stopping with GnRHa treatment are expected results and reflect the positive effect of this treatment on the height prognosis.
There are no randomized controlled studies evaluating the efficacy of GnRHa treatment in terms of height gain and most studies are conducted by comparing final height and the height before PAH treatment (4). Klein et al. (40) showed that a gain in adult height was achieved with basal PAH 149.3±9.6 cm, final height 159.8±7.6 cm compared to pretreatment PAH in patients with PP receiving a 2-year GnRHa treatment and the height prognosis was affected positively by treatment. In the present study, an average of 5.7 cm height gain in the idiopathic CPP group and 4.8 cm height gain in the organic CPP group were obtained with a 2-year GnRHa treatment, which is compatible with the literature (Table V) . It was thought that GnRHa treatment was effective in terms of height gain in patients with CPP with the height SDS and PAH increase according to bone age.
Study Limitations
The limitations of the present study are that the study was retrospective, the number of patients was low especially in the organic CPP group, there was no control group, it included a relatively short duration of treatment, and there was a lack of follow-up after the completion of the treatment. There is a need for prospective studies which also include serum adipokine levels for the interpretation of weight changes associated with GnRHa treatment including more patients and control groups.
Conclusion
The prevalence of obesity was higher in patients with CPP during the admission, and obesity is a risk factor for PP. BMI SDS increases with GnRHa treatment in CPP. Patients with organic CPP are more prone to weight and BMI increase. Patients with CPP receiving GnRHa treatment should be followed up for weight gain and obesity development and necessary precautions should be taken.
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